Hospital consolidation has become a popular target in the debate over rising healthcare costs. Critics argue that mergers reduce competition, increase prices, and leave patients with fewer choices. These are legitimate concerns. But they do not justify treating every hospital merger as bad healthcare policy before examining its likely effects.
The question is not whether hospital consolidation is inherently good or bad. It is whether a particular transaction will improve or undermine competition, affordability, access, and quality. Hospital mergers should be judged on their individual merits, not on a political presumption that consolidation is inherently harmful.
There are sound reasons to scrutinize hospital consolidation. When competing hospitals combine, the resulting system may gain bargaining power over insurers, demand higher reimbursement rates, and face less pressure to improve efficiency. Patients may have fewer alternatives, while employers and insurers struggle to negotiate affordable coverage. Research has documented price increases following certain hospital mergers, particularly when transactions weaken meaningful competition.
These risks are real, and antitrust enforcement has an essential role in preventing mergers that harm patients. But evidence that some transactions undermine competition does not establish that all mergers produce the same results.
The central flaw in the debate over hospital consolidation is the assumption that mergers can be judged by a pre-determined standard – i.e., consolidation is bad for patients. In the public discussion over healthcare costs, treating all hospital consolidation as interchangeable might satisfy a political argument or offer political cover for policymakers, but it does not address the real issues impacting patients. The test as to whether a merger is good or bad must be based on access to affordable care.
That is why regulators should focus on the likely consequences of each transaction, not on whether consolidation fits a preferred political narrative – the ‘patient test’ is all that matters.
How should be apply the ‘patient test’? By the evidence. Regulators should examine local market concentration, patients' realistic alternatives, insurers' negotiating power, overlapping services, travel distances, hospital finances, and the potential effects on prices, quality, and access. They should demand credible support for promised efficiencies and assess whether claimed improvements in coordination, clinical capabilities, or investment are likely to materialize.
This approach is not a retreat from antitrust enforcement. It is what effective enforcement requires. Blocking a merger simply because it increases the size of a health system is no more evidence-based than approving one because executives promise savings or better care. Regulators should establish the likely competitive harm of a proposed transaction, weigh its substantiated benefits, and make a decision grounded in the facts. Some mergers should be blocked; others may deserve approval. Still others may require enforceable commitments to protect patients and preserve access.
The goal should be a healthcare market that rewards efficiency, innovation, access, and quality—not one that favors a predetermined number of independent hospitals. The relevant questions are whether patients have meaningful alternatives, insurers can negotiate effectively, new providers can enter the market, and hospitals face real incentives to control costs and improve care.
Ultimately, the standard should be straightforward: What does the evidence show this transaction will mean for patients? Will it improve access and quality? Generate credible efficiencies? Preserve essential services?
Those answers will vary by market and by merger. The public discussion should be capable of recognizing that. A blanket political verdict against consolidation risks rejecting beneficial arrangements; a blanket presumption in its favor risks excusing deals that harm patients. Neither serves the public interest.
Patients deserve decisions based on the merits of each transaction, not ideology about the size or structure of health care organizations. Rigorous antitrust enforcement and careful, case-by-case review can protect competition while allowing demonstrable benefits to count.
If the goal is more affordable care, broader access, and better outcomes, hospital mergers must be judged on what they are likely to deliver—not condemned or celebrated simply because consolidation has occurred. It’s all about the patients.
